Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF)

J. Beier, K. M. Beeh, I. C. Haas, O. Kornmann, P. Micke, R. Buhl (Mainz, Germany)

Source: Annual Congress 2001 - Inflammatory and genetic mechanisms in pulmonary fibrosis
Session: Inflammatory and genetic mechanisms in pulmonary fibrosis
Session type: Thematic Poster Session
Number: 2778
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Beier, K. M. Beeh, I. C. Haas, O. Kornmann, P. Micke, R. Buhl (Mainz, Germany). Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2001; 16: Suppl. 31, 2778

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006


Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018

Changes of BAL findings as no progression marker in idiopathic pulmonary fibrosis (IPF) patients treated with IFN-g
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006


Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009

Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017

A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010

Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015



Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006


Respiratory infections in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009

Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)?
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005

Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011

Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Source: Eur Respir Rev 2009; 18: 129-132
Year: 2009



VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007